Marijuana Expert Witnesses in Virginia

This qualified expert of Addiction Psychiatry completed his undergrad and MD in Canada at the McGill University. He completed his post-doc Residency and Fellowship in Psychiatry and Pharmacology in Canada at the University of Toronto. He is Board Certified in the US in Psychiatry & Neurology and in Addiction Psychiatry. He is a member of multiple Addiction Psychiatry Medical Associations and has published 200+ Publications on Addiction Psychiatry Research. He is currently a Professor of Psychiatry at a Top Medical University, the Director of a Top University's Addiction Center, and is the Chief Psychiatrist and Associate Medical Director at a Top University Hospital.

This highly qualified expert has years of experience in using animal models to study diabetes. He received his PhD degree from Ohio State University and completed his fellowship training in physiology and biophysics at the University of Illinois. He has published 98+ peer-reviewed journal articles and serves as a reviewer for 26+ renowned medical journals. He has been listed in "Who's Who in America" for science and engineering and lectures nationwide. Currently, he is a professor of pharmaceutical science and research and the director of pharmacology and toxicology at a major university. He is also the director of the Center for Diagnostic Nanosystems and the associate director of the Cell Differentiation and Development Center at the same institution. Additionally, he is the biological sciences laboratory supervisor at another major university.

This expert is board certified psychiatrist and addiction specialist, and also is certified by the American Board of Disability Analysts. He is an expert in handling capital, personal injury, loss mitigation, malpractice and negligence cases that involve the use of abused substances (especially, opiates, alcohol, hallucinogens, and stimulants), prescribed pharmacological agents, and in the general field of psychiatric and brain disease. This expert also is a leading neuroscientist and neuropsychopharmacologist. He can provide expert testimony on the effects of different brain states and function, in both health and disease, and their potential association with with legal culpability and liability. He currently serves as the Chairman of the Department of Psychiatry at a leading university in the USA, and has over 12 years experience as Chairman in Psychiatry Departments in the USA. His research focus is in the neuropsychopharmacology of addiction, addiction and pain, pain treatment, impact of genetics on human behavior, the basic, molecular, and the brain imaging sciences related to the functioning of the brain in health, disease and addiction. In recognition of his academic, scholarly and professional achievement, he is a Fellow of the Collegium Internationale Neuro-psychopharmacologicum and a Distinguished Fellow of the American Psychiatric Association. He is the recipient of numerous professional and scientific awards, including the Jack Mendelson Award at the NIH, which is awarded to individuals who have made distinguished contributions to our understanding of the science of addiction. He has an h-index of 46, and 11829 citations of his published work.

A 17-year veteran of the U.S. Food and Drug Administration (FDA), this expert served as the Regulatory Counsel to the Associate Commissioner for Regulatory Affairs, and previously, in scientific, inspectional, compliance and criminal and civil enforcement capacities as an FDA Consumer Safety Officer (CSO), Compliance Officer (CO), a Senior Special Agent (SA) with the Office of Criminal Investigations (OCI) and as an analytical regulatory microbiologist. During his last three years at FDA he spearheaded the agency's integration efforts with Customs and USDA on crosscutting interagency enforcement and operational issues; served as the FDA's point-person in managing the intersection of imports and FDA's new bioterrorism regulations; established joint agency and industry working groups to evaluate counterfeiting and tampering risks to food and drug distribution supply chains; was the agency lead in its strategic planning efforts to reinvent the FDA's import programs; wrote the initial statement of work and acted as program manager over the FDA's new PREDICT, risk-based electronic entry screening system; and directed the development of the FDA's agency-wide Risk-based Import Strategic Plan designed to improve compliance of foods, dietary supplements, drugs, medical devices, cosmetics, and biological products imported into the U.S. As CEO of a FDA consulting firm and Founder of an affiliated law firm, he currently represents domestic and foreign companies of all sizes, assisting them in identifying USDA, FDA, Federal Trade Commission (FTC), Environmental Protection Agency (EPA), and state requirements. He focuses his practice on FDA matters, including but not limited to: matters relating to FDA inspections, FDA criminal, regulatory and administrative enforcement actions for medical devices, drugs, cosmetics, alcohol, tobacco, dietary supplements, and foods.

This highly-qualified expert has her Masters, PhD and postdoctoral training in the area of environmental toxicology. She continues to work in this area, focusing primarily on the long term effects following exposures to halogenated hydrocarbons. In addition, her research activities involve the study of drug metabolism and nuclear hormone receptors. Her teaching activities (to dental, medical, graduate and undergraduate students), encompass the disciplines of toxicology and pharmacology. The focus here is understanding how exposures to certain chemicals (drugs or toxicants) elicit specific effects resulting in either therapeutic benefit or damage to certain tissues and how that impacts overall health.

This expert has been practicing toxicology for over 40 years. She holds a Master of Science in Clinical Chemistry as well as a Ph.D. in Toxicology, and an honorary doctoral degree in Medicine and Surgery from the Faculty of Medicine, University of Helsinki. She serves on the World Anti-Doping Agency's Prohibited List Committee, the National Commission on Forensic Sciences, the Organization of Scientific Area Committee on Toxicology, Transportation Research Board Committee on Alcohol and Other Drugs, and the National Safety Council's Alcohol, Drugs and Impairment Division Executive Board. She was a President of the International Association of Forensic Toxicologists, she is also a former President of the Society of Forensic Toxicologist and past Chair of the Toxicology Section of the American Academy of Forensic Sciences. She has published over 445 peer-reviewed articles and has presented more than 500 abstracts at national and international meetings, and she sits on the Editorial Board of multiple toxicological and chemical journals. She recently retired as Chief of Chemistry and Drug Metabolism, National Institute on Drug Abuse, National Institutes of Health. She serves as an Adjunct Professor at a major medical university. She consults with the US Department of Transportation, NMS Labs, and other diagnostic companies around the world. The journal Clinical Chemistry identified her as an inspiring mind.

This highly experienced expert in drug discovery and drug development earned his PhD in Pharmacology from Yale University and thereafter completed a postgraduate fellowship at the University of Michigan. He previously served as the Chief Scientific Officer of Adherex Technologies, International Vice President of Cancer Research at Glaxo Wellcome (now GSK) and Associate Division Director of Experimental Therapy at Burroughs Wellcome. He is a member of the American Chemical Society, the American Association for Cancer Research, and the American Society of Clinical Oncology. He has extensive experience in preclinical and clinical research and legal consulting.

This expert has over 15 years experience in academia as it relates to Pharmacology. He has been accredited with the discovery of the RGS protein family, leading to 4 issued patents and numerous publications. In 2004 he was awarded the John Abel Award as an Outstanding American Pharmacologist under 40, from the American Society for Pharmacology & Experimental Therapeutics (ASPET). He is currently not only a Professor of Pharmacology, but also the Chair of the department and Director of the MD/PhD Scholars program at a University in West Virginia.

This expert has 15 years of experience in clinical pharmacotherapy. He received his PharmD from Campbell University School of Pharmacy and completed his residency in pharmacy practice at Wake Forest University's Baptist Medical Center. He is board certified as a pharmacotherapy specialist. He began his career as a decentralized clinical pharmacist at Wake Forest University before accepting a position as an assistant professor of clinical pharmacy practice and the anticoagulation clinic director at Auburn University. He then went on to be an assistant professor, and eventually associate professor, of clinical pharmacy practice at East Tennessee State University. This expert is heavily involved in pharmacological research, having authored several peer-reviewed articles and presenting on numerous posters at various pharmacy conferences. He currently serves as the vice chair of pharmacy practice and professor of clinical pharmacy practice at a pharmacy program at a Tennessee medical school.

This highly-qualified expert has over 15 years of experience as a pharmacist dealing with issues like medication safety, medication errors, and medication policy. She earned her PharmD from the University of North Carolina before completing a drug information specialty residency at Thomas Jefferson University Hospital. This expert is a licensed pharmacist in North Carolina and is certified by the American Heart Association in basic life support. She is active in her field as a member of the American Society of Health-System Pharmacists, a researcher on several pharmacy research studies, an author of multiple pharmacy publications, and a speaker at several industry conferences throughout her career. She has formerly served as a clinical instructor at the University of the Sciences in Philadelphia, a clinical pharmacist in the ambulatory setting at the Duke Outpatient Clinic, and a clinical pharmacist in medication safety at Duke University Medical Center. This expert currently serves as a clinical pharmacist for drug information at a university-affiliated medical center and as the preceptor for the drug information rotation at two North Carolina universities.

This expert is an internationally recognized human resources expert and is a trained Ohio Drug Free Workplace trainer. She earned a JD from Taft Law School and a MBA from York College of Pennsylvania. She is well published on human resources issues, specifically relating to employment practices. She has served as the HR Vice President or Director for a number of large, for-profit and non-profit corporations and is currently the head of Human Resources for a major psychiatric institution.

This highly qualified expert has years of experience in the field of neuropharmacology. He received his PhD degree from the University of California, Santa Barbara, and completed his fellowship training at Harvard University. He is a member of various professional associations, including the American Society of Pharmacology and Experimental Therapeutics and the American Chemical Society. He has published 250+ peer reviewed journal articles and has 51+ US issued patents that focus particularly on neurological studies. He also serves as the editor-in-chief for ACS Chemical Neuroscience, lectures both nationally and internationally and has received multiple honors for his outstanding work, including the John J. Abel award in pharmacology. He is the former co-director of the Synthesis Facility at the Vanderbilt Institute of Chemical Biology and the former senior organic chemist at Eli Lilly & Co. Currently, he is a professor of pharmacology and chemistry at a major university, where he is also the director of medicinal chemistry and DMPK at the Center for Neuroscience Drug Discovery. Additionally, he is the director of drug discovery at a major science institute in Tennessee.